What's in Aptose Biosciences Inc.'s pipeline?

Aptose Biosciences Inc. has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Aptose Biosciences Inc.'s portfolio?

Top competitors by shared drug class: Candel Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aptose-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Aptose Biosciences Inc. — Portfolio Competitive Intelligence Brief

Aptose Biosciences Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Virulizin®	Virulizin®	phase 3	Oncolytic virus		Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Candel Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aptose Biosciences Inc.:

Cite this brief

Drug Landscape (2026). Aptose Biosciences Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aptose-biosciences-inc. Accessed 2026-05-16.